MSH2 and breast cancer: Moreover, HER2 enriched subtype was significantly associated with hMSH2 rs4987188 (p = 0.028) (Table 8), and Gly/Asp (GA) genotype decreased risk of developing BC almost 6‐fold in HER2 enriched subtype patients compared to non‐HER2 enriched subtype counterparts (OR = 0.47, CI 95% = 0.26–0.94, p = 0.033).